text:
Journal of Cancer Therapy > Vol.6 No.2, February 2015
Genetically Targeted Fractionated Chemotherapy ()
Aaron J. Smith, John Oertle, Dino Prato*
Envita, Scottsdale, USA.
DOI: 10.4236/jct.2015.62021 PDF HTML XML 4,508 Downloads 8,185 Views Citations
Complex and late stage cancer patients are in need of novel methods of selecting and administering chemotherapy particularly for those patients who are refractory to current treatment methods. The use of biomarkers to enhance decision making with regard to the molecular profile of a person's cancer is becoming more important in the practice of oncology. The standard for the last several decades is to elect chemotherapeutic agents based on staging and histological identification of the primary cancer site alone versus utilizing the genetic and molecular profile information along with histological primary cancer site and staging to select chemotherapy regimens. Cancers are caused by mutations that occur within cells and therefore selecting treatment based on mutations and not primary cancer site alone can provide advantages that may have gone overlooked. As time progresses, more biomarkers continue to be discovered which can lead to more targets for drugs either currently on the market or clinical trials. In addition to advancements made in the progression of cancer treatment with utilizing molecular profiles effectively, there are other therapeutic strategies that have been postulated as advanced effective ways to administer chemotherapy. These strategies provide chemotherapy to patients while fasting, giving insulin or other biological response modifiers adjunctively prior to chemotherapy for enhanced targeting, and giving chemotherapy in micro-doses to allow for increased frequency of administration and the utilization of multiple targeted chemotherapeutic agents concurrently. In this paper we will discuss these topics and explain their benefits in addition to the evidence that supports these treatments. A review on biomarkers and cancer cell metabolism is discussed as it relates to providing a framework for what constitutes a biomarker in addition to what metabolic processes are related to fasting and administering insulin with chemotherapy. The information provided in this document is designed to illuminate and provide evidence for various methodologies that are underserved in the treatment of cancer.
Biomarkers, Molecular Profile, Cancer, Chemotherapy, Glycolysis, Insulin
Smith, A. , Oertle, J. and Prato, D. (2015) Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 6, 182-198. doi: 10.4236/jct.2015.62021.
[1] Weeks, J.C., Catalano, P.J., Cronin, A., Finkelman, M.D., Mack, J.W., Keating, N.L. and Schrag, D. (2012) Pateints' Expectation about Effects of Chemotherapy for Advanced Cancer. The New England Journal of Medicine, 367, 1616-1625. http://dx.doi.org/10.1056/NEJMoa1204410
[2] Srinivas, P.R., Kramer, B.S. and Srivastava, S. (2001) Trends in Biomarker Research for Cancer Detection. The Lancet Oncology, 2, 698-704. http://dx.doi.org/10.1016/S1470-2045(01)00560-5
[3] Cho, W.S.C. (2007) Contribution of Oncoproteomics to Cancer Biomarker Discovery. Molecular Cancer, 6, 25. http://dx.doi.org/10.1186/1476-4598-6-25
[4] Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 100, 57-70.
http://dx.doi.org/10.1016/S0092-8674(00)81683-9
[5] Ludwig, J.A. and John, N. (2005) Weinstein Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature Reviews Cancer, 5, 845-856. http://dx.doi.org/10.1038/nrc1739
[6] Egger, G., Liang, G., Aparicio, A. and Jones, P.A. (2004) Epigenetics in Human Disease and Prospects for Epigenetic Therapy. Nature, 429, 457-463. http://dx.doi.org/10.1038/nature02625
[7] Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., et al. (2005) Presence of Circulating Tumor Cells (CTC) in Metastatic Breast Cancer (MBC) Predicts Rapid Progression and Poor Prognosis. Journal of Clinical Oncology, 23, 524.
[8] Liyanage, U.K., Moore, T.T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., et al. (2002) Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma. Journal of Immunology, 169, 2756-2761.
http://dx.doi.org/10.4049/jimmunol.169.5.2756
[9] Siddiqui, S.A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S.M., Krambeck, A.E., et al. (2007) Tumor-Infiltrating Foxp3–CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma. Clinical Cancer Research, 13, 2075-2081. http://dx.doi.org/10.1158/1078-0432.CCR-06-2139
[10] Woo, E.Y., Yeh, H., Chu, C.S., Schlienger, K., Carroll, R.G., Riley, J.L., et al. (2002) Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation. Journal of Immunology, 168, 4272-4276. http://dx.doi.org/10.4049/jimmunol.168.9.4272
[11] Wolf, A.M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E. and Grubeck-Loebenstein, B. (2003) Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients. Clinical Cancer Research, 9, 606-612.
[12] Viguier, M., Lema?tre, F., Verola, O., Cho, M.S., Gorochov, G., Dubertret, L., et al. (2004) Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells. Journal of Immunology, 173, 1444-1453. http://dx.doi.org/10.4049/jimmunol.173.2.1444
[13] Ormandy, L.A., Hillemann, T., Wedemeyer, H., Manns, M.P., Greten, T.F. and Korangy, F. (2005) Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Research, 65, 2457-1464. http://dx.doi.org/10.1158/0008-5472.CAN-04-3232
[14] Joosten, S.A. and Ottenhoff, T.H.M. (2008) Human CD4 and CD8 Regulatory T Cells in Infectious Diseases and Vaccination. Human Immunology, 69, 760-770. http://dx.doi.org/10.1016/j.humimm.2008.07.017
[15] Bishop, J.M. (1987) The Molecular Genetics of Cancer. Science, 235, 305-311.
http://dx.doi.org/10.1126/science.3541204
[16] Whitfield, M.L., George, L.K., Grant, G.D. and Perou, C.M. (2006) Common Markers of Proliferation. Nature Reviews Cancer, 6, 99-106. http://dx.doi.org/10.1038/nrc1802
[17] Dunning, A.M., Healey, C.S., Pharoah, P.D.P., Teare, D.M., Ponder, B.A.J. and Easton, D.F. (1999) A Systematic Review of Genetic Polymorphisms and Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 8, 843-854.
[18] Toru, H., Masaharu, Y., Shinji, T. and Kazuaki, C. (2008) Genetic Polymorphisms and Head and Neck Cancer Risk. International Journal of Oncology, 32, 945-973.
[19] Ignatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., et al. (2007) Different Prognostic Value of Cytokeratin-19 mRNA Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. Journal of Clinical Oncology, 25, 5194-5202.
http://dx.doi.org/10.1200/JCO.2007.11.7762
[20] Delys, L., Detours, V., Franc, B., Thomas, G., Bogdanova, T., Tronko, M., et al. (2007) Gene Expression and the Biological Phenotype of Papillary Thyroid Carcinomas. Oncogene, 26, 7894-7903.
http://dx.doi.org/10.1038/sj.onc.1210588
[21] Dwarakanath, B.S., Manogaran, P.S., Das, S., Das, B.S. and Jain, V. (1994) Heterogeneity in DNA Content and Proliferative Status of Human Brain Tumors. Indian Journal of Medical Research, 100, 279-286.
[22] Weber, J.L. and May, P.E. (1989) Abundant Class of Human DNA Polymorphisms Which Can Be Typed Using Polymerase Chain Reaction. American Journal of Human Genetics, 44, 388-396.
[23] Arzimanoglou, I.I., Gilbert, F. and Barger, H.R. (1998) Microsatellite Instability in Human Solid Tumors. Cancer, 82, 1808-1820.
http://dx.doi.org/10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J
[24] Arnold, K. (2000) Biomarker for Esophageal Cancer Found in Bloodstream. Journal of the National Cancer Institute, 92, 1787.
[25] Fearnhead, N.S., Britton, M.P. and Bodmer, W.F. (2001) The ABC of APC. Human Molecular Genetics, 10, 721-733. http://dx.doi.org/10.1093/hmg/10.7.721
[26] Kim, H., Kwon, Y.M., Kim, J.S., Lee, H., Park, J.H., Shim, Y.M., et al. (2004) Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 2363-2370. http://dx.doi.org/10.1200/JCO.2004.10.077
[27] Ehrlich, M. (2002) DNA Methylation in Cancer: Too Much, but Also Too Little. Oncogene, 21, 5400-5413. http://dx.doi.org/10.1038/sj.onc.1205651
[28] Cuezva, J.M., Krajewska, M., Heredia, M.L., Krajewski, S., Kim, G.S.H., Zapata, J.M., et al. (2002) The Bioenergetic Signature of Cancer: A Marker of Tumor Progression. Cancer Research, 62, 6674-6681.
[29] Reivich, M., Kuhl, D., Wolf, A., Greenberg, J., Phelps, M., Ido, T., et al. (1977) Measurement of Local Cerebral Glucose Metabolism in Man with 18F-2-Fluoro-2-deoxy-D-glucose. Acta neurologica Scandinavica. Supplementum, 64, 190-191.
[30] Dichiro, G., Brooks, R.A., Patronas, N.T., Bairamian, D., Kornblith, P.L., Smith, B.H., et al. (1984) Issues in the in Vivo Measurement of Glucose Metabolism of Human Central Nervous System Tumors. Annals of Neurology, 15, 138-146. http://dx.doi.org/10.1002/ana.410150727
[31] Padma, M.V., Said, S., Jacobs, M., Hwang, D.R., Dunigan, K., Satter, M., et al. (2003) Prediction of Pathology and Survival by FDG PET in Gliomas. Journal of Neuro-Oncology, 64, 227-237.
http://dx.doi.org/10.1023/A:1025665820001
[32] Spence, A.M., Muzi, M., Graham, M.M., O'Sullivan, F., Link, J.M., Lewellen, T.K., et al. (2002) 2-[18F]Fluoro-2-deoxyglucose and Glucose Uptake in Malignant Gliomas before and after Radiotherapy: Correlation with Outcome. Clinical Cancer Research, 8, 971-979.
[33] Weber, W.A. (2006) Positron Emission Tomography as an Imaging Biomarker. Journal of Clinical Oncology, 20, 3282-3292. http://dx.doi.org/10.1200/JCO.2006.06.6068
[34] Stricker, T., Vatenacci, D.V.T. and Seiwert, T.Y. (2011) Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology, 38, 173-185.
http://dx.doi.org/10.1053/j.seminoncol.2011.01.013
[35] Thurlimann, B., Goldhirsch, A., Castiglione, M., Hsu-Schmitz, S.F., Cavalli, F., Bonnefoi, H., et al. (1997) Formestane versus Megestrol Acetate in Postmenopausal Breast Cancer Patients after Failure of Tamoxifen: A Phase III Prospective Randomised Cross over Trial of Second-Line Hormonal Treatment (SAKK 20/90). European Journal of Cancer, 33, 1017-1024.
[36] Stuart, N.S.A., Warwick, J., Blackledge, G.R.P., Spooner, D., Keen, C., Earl, H., et al. (1996) A Randomized Phase III Cross-Over Study of Tamoxifen versus Megestrol Acetate in Advanced and Recurrent Breast Cancer. European Journal of Cancer, 32, 1888-1892.http://dx.doi.org/10.1016/0959-8049(96)00191-8
[37] Cuzick, J. (2007) LHRH-Agonists in Early Breast Cancer Overview Group. Use of Luteinising-Hormone-Releasing Hormone Agonists as Adjuvant Treatment in Premenopausal Patients with Hormone-Receptor-Positive Breast Cancer: A Meta-Analysis of Individual Patient Data from Randomised Adjuvant Trials. The Lancet, 369, 1711-1723. http://dx.doi.org/10.1016/S0140-6736(07)60778-8
[38] Lewis, J.D., Chagpar, A.B., Shaughnessy, E.A., Nurko, J., McMasters, K. and Edwards, M.J. (2010) Excellent Outcomes with Adjuvant Toremifene or Tamoxifen in Early Stage Breast Cancer. Cancer, 116, 2307-2315.
[39] Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Allred, C., et al. (2008) Relationship between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status with Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 26, 1059-1065. http://dx.doi.org/10.1200/JCO.2007.12.9437
[40] Bartlett, J.M.S., Rea, D., et al. (2011) Estrogen Receptor and Progesterone Receptor as Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 29, 1531-1538.
[41] Coombes, R.C., Kilburn, L.S., Snowdon, C.F., Paridaens, R., Coleman, R.E., Bliss, J.M., et al. (2007) Survival and Safety of Exemestane versus Tamoxifen after 2-3 Years' Tamoxifen Treatment (Intergroup Exemestane Study): A Randomized Controlled Trial. The Lancet, 369, 559-570.
[42] Viale, G., Regan, M.M., Maiorano, E., Mastropasqua, M.G., Golouh, R., Regan, M.M., et al. (2008) Chemoendocrine Compared with Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group. Journal of Clinical Oncology, 26, 1404-1410.
[43] Anderson, H., Hills, M., Zabaglo, L., A'Hern, R., Leary, A.F., Dowsett, M., et al. (2011) Relationship between Estrogen Receptor, Progesterone Receptor, HER-2 and Ki67 Expression and Efficacy of Aromatase Inhibitors in Advanced Breast Cancer. Annals of Oncology, 22, 1770-1776.
http://dx.doi.org/10.1093/annonc/mdq700
[44] Stendahl, M., Ryden, L., Nordenskjold, B., Ebbe J?nsson, P., Landberg, G. and Jirstrom, K. (2006) High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Clinical Cancer Research, 12, 4614-4618.
http://dx.doi.org/10.1158/1078-0432.CCR-06-0248
[45] Yamashita, H., Ando, Y., Nishio, M., Zhang, Z., Hamaguchi, M., Mita, K., et al. (2006) Immunohisto- chemical Evaluation of Hormone Receptor Status for Predicting Response to Endocrine Therapy in Metastatic Breast Cancer. Breast Cancer, 13, 74-83. http://dx.doi.org/10.2325/jbcs.13.74
[46] Yu, Z., Yang, Q., et al. (2005) Thymidylate Synthase Predicts for Clinical Outcome in Invasive Breast Cancer. Histology and Histopathology, 20, 871-878.
[47] Chen, C.Y., Yang, P.C., et al. (2011) Thymidylate Synthase and Dihydrofolate Reductase Expression in Non-Small Cell Lung Carcinoma: The Association with Treatment Efficacy of Pemetrexed. Lung Cancer, 74, 132-138. http://dx.doi.org/10.1016/j.lungcan.2011.01.024
[48] Lee, S.J., Im, Y.H., et al. (2011) Thymidylate Synthase and Thymidine Phosphorylase as Predictive Markers of Capecitabine Monotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Cancer Chemotherapy and Pharmacology, 68, 743-751. http://dx.doi.org/10.1007/s00280-010-1545-0
[49] Penson, R.T., Seiden, M.V., et al. (2004) Expression of Multidrug Resistance-1 Protein Inversely Correlates with Paclitaxel Response and Survival in Ovarian Cancer Patients: A Study in Serial Samples. Gynecologic Oncology, 93, 98-106. http://dx.doi.org/10.1016/j.ygyno.2003.11.053
[50] Yeh, J.J., Hsu, W.H., Wang, J.J., Ho, S.T. and Kao, A. (2003) Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression. Respiration, 70, 32-35. http://dx.doi.org/10.1159/000068411
[51] Von Hoff, D.D., Hidalgo, M., et al. (2011) Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 29, 4548-4554. http://dx.doi.org/10.1200/JCO.2011.36.5742
[52] Desai, N., Trieu, V., Damascelli, B. and Soon-Shiong, P. (2009) SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Translational Oncology, 2, 59-64. http://dx.doi.org/10.1593/tlo.09109
[53] Seve, P., Dumontet, C., et al. (2005) Class III β-Tubulin Expression in Tumor Cells Predicts Response and Outcome in Patients with Non-Small Cell Lung Cancer Receiving Paclitaxel. Molecular Cancer Therapeutics, 4, 2001-2007. http://dx.doi.org/10.1158/1535-7163.MCT-05-0244
[54] Ploussard, G., de la Taille, A., et al. (2010) Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Clinical Cancer Research, 70, 9253-9264.
[55] Gao, S., Zhao, X., Lin, B., Hu, Z., Yan, L. and Gao, J. (2012) Clinical Implications of REST and TUBB3 in Ovarian Cancer and Its Relationship to Paclitaxel Resistance. Tumor Biology, 33, 1759-1765. http://dx.doi.org/10.1007/s13277-012-0435-y
[56] Zhang, H.L., Ruan, L., Zheng, L-M., Whyte, D., Tzeng, C-M. and Zhou, X.W. (2012) Association between Class III β-Tubulin Expression and Response to Paclitaxel/Vinorelbine-Based Chemotherapy for Non-Small Cell Lung Cancer: A Meta-Analysis. Lung Cancer, 77, 9-15.
http://dx.doi.org/10.1016/j.lungcan.2012.01.005
[57] Kulkarni, S.A., Ross, D.T., et al. (2009) TLE3 as a Candidate Biomarker of Response to Taxane Therapy. Breast Cancer Research, 11, R17. http://dx.doi.org/10.1186/bcr2241
[58] Gong, W., Dong, J., et al. (2012) RRM1 Expression and Clinical Outcome of Gemcitabine-Containing Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Lung Cancer, 75, 374-380. http://dx.doi.org/10.1016/j.lungcan.2011.08.003
[59] Ataka, M., Katano, K., et al. (2007) Topoisomerase I Protein Expression and Prognosis of Patients with Colorectal Cancer. Yonago Acta Medica, 50, 81-87.
[60] Braun, M.S., Seymour, M.T., et al. (2008) Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results from the UK MRC FOCUS Trial. Journal of Clinical Oncology, 26, 2690-2698. http://dx.doi.org/10.1200/JCO.2007.15.5580
[61] Kostopoulos, I., Fountzilas, G., et al. (2009) Topoisomerase I but Not Thymidylate Synthase Is Associated with Improved Outcome in Patients with Resected Colorectal Cancer Treated with Irinotecan Containing Adjuvant Chemotherapy. BMC Cancer, 9, 339. http://dx.doi.org/10.1186/1471-2407-9-339
[62] Baselga, J., Swain, S.M., et al. (2012) Pertuzumab Plus Trastumab Plus Docetaxel for Metastatic Breast Cancer. The New England Journal of Medicine, 36, 109-119. http://dx.doi.org/10.1056/NEJMoa1113216
[63] National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 2.2013.
[64] Bachelot, T., Pujade-Lauraine, E., et al. (2012) Randomized Phase II Trial of Everolimus in Combination with Tamoxifen in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors: A GINECO Study. Journal of Clinical Oncology, 30, 2718-2724 http://dx.doi.org/10.1200/JCO.2011.39.0708
[65] Wolff, A.C., Hayes, D.F., et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013.
[66] Janku, F., Kurzrock, R., et al. (2012) PI3K/AKT/mTOR Inhibitors in Patients with Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology, 30, 777-782.
[67] Janku, F., Kurzrock, R., et al. (2012) PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research, 73, 276-284. http://dx.doi.org/10.1158/0008-5472.CAN-12-1726
[68] Moroney, J.W., Kurzrock, R., et al. (2011) A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. Clinical Cancer Research, 17, 6840-6846. http://dx.doi.org/10.1158/1078-0432.CCR-11-0666
[69] Guo, J., Qin, S., et al. (2011) Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients with Metastatic Melanoma Harboring c-Kit Mutation or Amplification. Journal of Clinical Oncology, 29, 2904-2909. http://dx.doi.org/10.1200/JCO.2010.33.9275
[70] Carvajal, R.D., Schwartz, G.K., et al. (2011) KIT as a Therapeutic Target in Metastatic Melanoma. Journal of the American Medical Association, 305, 2327-2334. http://dx.doi.org/10.1001/jama.2011.746
[71] Debiec-Rychter, M., Judson, I., et al. (2006) KIT Mutations and Dose Selection for Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours. European Journal of Cancer, 42, 1093-1103.
http://dx.doi.org/10.1016/j.ejca.2006.01.030
[72] Heinrich, M.C., Fletcher, J.A., et al. (2008) Correlation of Kinase Genotype and Clinical Outcome in North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Journal of Clinical Oncology, 26, 5360-5367. http://dx.doi.org/10.1200/JCO.2008.17.4284
[73] Cassier, P.A., Hohenberger, P., et al. (2012) Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clinical Cancer Research, 18, 4458-4464. http://dx.doi.org/10.1158/1078-0432.CCR-11-3025
[74] Wells, S.A., Schlumberger, M.J., et al. (2012) Vandetanib in Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology, 30, 134-141. http://dx.doi.org/10.1200/JCO.2011.35.5040
[75] Gennari, A., Bruzzi, P., et al. (2008) HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 100, 14-20. http://dx.doi.org/10.1093/jnci/djm252
[76] Press, M.F., Slamon, D.J., et al. (2011) Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association with Responsiveness to Anthracycline Based Chemotherapy. Journal of Clinical Oncology, 29, 859-867. http://dx.doi.org/10.1200/JCO.2009.27.5644
[77] Akimoto, M., Saisho, H., et al. (2006) Relationship between Therapeutic Efficacy of Arterial Infusion Chemotherapy and Expression of P-Glycoprotein and p53 Protein in Advanced Hepatocellular Carcinoma. World Journal of Gastroenterology, 12, 868-873.
[78] Mittal, M.K., Singh, J.P., et al. (2005) Role of p-Glycoprotein Expression in Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer—A Prospective Clinical Study. World Journal of Surgical Oncology, 3, 61. http://dx.doi.org/10.1186/1477-7819-3-61
[79] O'Malley, F.P., Pritchard, K.I., et al. (2011) Topoisomerase II Alpha Protein and Responsiveness of Breast Cancer to Adjuvant Chemotherapy with CEF Compared to CMF in the NCIC CTG Randomized MA.5 Adjuvant Trial. Breast Cancer Research and Treatment, 128, 401-409. http://dx.doi.org/10.1007/s10549-011-1511-5
[80] Rodrigo, R.S., Axel L.C., et al. (2011) Topoisomerase II-Alpha Protein Expression and Histological Response Following Doxorubicin-Based Induction Chemotherapy Predict Survival of Locally Advanced Soft Tissues Sarcomas. European Journal of Cancer, 47, 1319-1327. http://dx.doi.org/10.1016/j.ejca.2011.02.010
[81] Buckingham, L.P., Bonomi, P., et al. (2007) The Prognostic Value of Chromosome 7 Polysomy in Non-Small Cell Lung Cancer Patients Treated with Gefitinib. Journal of Thoracic Oncology, 2, 414-422. http://dx.doi.org/10.1097/01.JTO.0000268675.02744.b0
[82] Verma, S., Blackwell, K., et al. (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine, 367, 1783-1791. http://dx.doi.org/10.1056/NEJMoa1209124
[83] Cortes, J., Baselga, J., et al. (2012) Pertuzumab Monotherapy after Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 30, 1594-1600. http://dx.doi.org/10.1200/JCO.2011.37.4207
[84] Bang, Y.J., Kang, Y.K., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. http://dx.doi.org/10.1016/S0140-6736(10)61121-X
[85] Yin, W., Jiang, Y., Shen, Z., Shao, Z. and Lu, J. (2011) Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials. PLoS ONE, 6, e21030. http://dx.doi.org/10.1371/journal.pone.0021030
[86] Slamon, D., Buyse, M., et al. (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. The New England Journal of Medicine, 365, 1273-1283. http://dx.doi.org/10.1056/NEJMoa0910383
[87] Hurvitz, S.A., Perez, E.A., et al. (2013) Phase II Randomized Study of Trastuzumab Emtansine versus Trastuzumab plus Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 31, 1157-1163.
[88] Johnston, S., Pegram, M., et al. (2009) Lapatinib Combined with Letrozole versus Letrozole and Placebo as First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 27, 5538-5546. http://dx.doi.org/10.1200/JCO.2009.23.3734
[89] Amir, E., Oca?a, A., Seruga, B., Freedman, O. and Clemons, M. (2010) Lapatinib and HER2 Status: Results of a Meta-Analysis of Randomized Phase III Trials in Metastatic Breast Cancer. Cancer Treatment Reviews, 36, 410-415. http://dx.doi.org/10.1016/j.ctrv.2009.12.012
[90] Press, M.F., Finn, R.S., et al. (2008) HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research, 14, 7861-7870. http://dx.doi.org/10.1158/1078-0432.CCR-08-1056
[91] Chinot, O.L., Barrie, M., et al. (2007) Correlation between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated with Neoadjuvant Temozolomide. Journal of Clinical Oncology, 25, 1470-1475. http://dx.doi.org/10.1200/JCO.2006.07.4807
[92] Busch, C., Geislerd, J., Lillehaug, J.R. and Lonning, P.E. (2010) MGMT Expression Levels Predict Disease Stabilisation, Progression-Free and Overall Survival in Patients with Advanced Melanomas Treated with DTIC. European Journal of Cancer, 46, 2127-2133. http://dx.doi.org/10.1016/j.ejca.2010.04.023?
[93] Warburg, O. (1923) Metabolism of Tumours. Biochemische Zeitschrift, 142, 317-333.
[94] Warburg, O. (1925) Iron, the Oxygen-Carrier of Respiration-Ferment. Science, 61, 575-582.
http://dx.doi.org/10.1126/science.61.1588.575
[95] Racker, E. (1972) Bioenergetics and the Problem of Tumor Growth. American Scientist, 60, 56-63.
[96] Turner, J.S. and Brittain, E.G. (1962) Oxygen as a Factor in Photosynthesis. Biological Reviews, 37, 130-170. http://dx.doi.org/10.1111/j.1469-185X.1962.tb01607.x
[97] Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F.M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., Emionite, L., Cabo, R. and Longo, V. (2012) Fasting Cycles Retard Growth of Tumor and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine, 4, 124-127.
[98] Cushman, S.W. and Wardzala, L.J. (1980) Potential Mechanism of Insulin Action on Glucose Transport in the Isolated Rat Adipose Cell. Apparent Translocation of Intracellular Transport Systems to the Plasma Membrane. Journal of Biological Chemistry, 255, 4758-4762.
[99] Suzuki, K. and Kono, T. (1980) Evidence That Insulin Causes Translocation of Glucose Transport Activity to the Plasma Membrane from an Intracellular Storage Site. Proceedings of the National Academy of Sciences of the United States of America, 77, 2542-2545. http://dx.doi.org/10.1073/pnas.77.5.2542
[100] Papa, V., Pezzino, V., Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G.B., Brand, R., Goldfine, I.D. and Vigneri, R. (1990) Elevated Insulin Receptor Content in Human Breast Cancer. Journal of Clinical Investigation, 86, 1503-1510. http://dx.doi.org/10.1172/JCI114868
[101] Belfiore, A. (2007) The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer. Current Pharmaceutical Design, 13, 671-686. http://dx.doi.org/10.2174/138161207780249173
[102] Grana, X. and Reddy, E.P. (1995) Cell Cycle Control in Mammalian Cells: Role of Cyclins, Cyclin Dependent Kinases (CDKs), Growth Suppressor Genes and Cyclin-Dependent Kinase Inhibitors (CKIs). Oncogene, 11, 211-219.
[103] Johnson, D.G. and Walker, C.L. (1999) Cyclins and Cell Cycle Checkpoints. Annual Review of Pharmacology and Toxicology, 39, 295-312. http://dx.doi.org/10.1146/annurev.pharmtox.39.1.295
[104] Kaldis, P., Russo, A.A., Chou, H.S., Pavletich, N.P. and Solomon, M.J. (1998) Human and Yeast Cdk-Activating Kinases (CAKs) Display Distinct Substrate Specificities. Molecular Biology of the Cell, 9, 2545-2560. http://dx.doi.org/10.1091/mbc.9.9.2545
[105] Hartwell, L.H. and Kastan, M.B. (1994) Cell Cycle Control and Cancer. Science, 266, 1821-1828. http://dx.doi.org/10.1126/science.7997877
[106] Harper, J. and Elledge, S.J. (1996) Cdk Inhibitors in Development and Cancer. Current Opinion in Genetics & Development, 6, 56-64. http://dx.doi.org/10.1016/S0959-437X(96)90011-8
[107] Senderowicz, A.M. (2002) Cyclin-Dependent Kinases as Targets for Cancer Therapy. In: Giaccone, G., Schilsky, R. and Sondel. P., Eds., Cancer Chemotherapy and Biological Response Modifiers Annual 20, Elsevier Science, New York, 169-188.
[108] Gliozzo, B., Sung, C.K., Scalia, P.L., Papa, V., Frasca, F., Sciacca, L., Giorgino, F., Milazzo, G., Goldfine, I.D., Vigneri, R. and Pezzino, V.J. (1998) Insulin-Stimulated Cell Growth in Insulin Receptor Substrate-1-Deficient ZR-75-1 Cells Is Mediated by a Phosphatidylinositol-3-Kinase-Independent Pathway. Journal of Cellular Biochemistry, 70, 268-280.
http://dx.doi.org/10.1002/(SICI)1097-4644(19980801)70:2<268::AID-JCB12>3.0.CO;2-J
[109] Bentel, J.M., Lebwohl, D.E., Cullen, K.J., Rubin, M.S., Rosen, N., Mendelsohn, J. and Miller, W.H. (1995) Insulin-Like Growth Factors Modulate the Growth Inhibitory Effects of Retinoic Acid on MCF-7 Breast Cancer Cells. Journal of Cellular Physiology, 165, 212-221. http://dx.doi.org/10.1002/jcp.1041650124
[110] Yang, X.F., Beamer, W.G., Huynh, H.T. and Pollak, M. (1996) Cancer Research, 56, 1509-1511.
[111] Pollak, M., Constantino, J., Polychronakos, C., Blauer, S.A., Guyda, H., Redmond, C., Fisher, B. and Margolese, R. (1990) Effect of Tamoxifen on Serum Insulinlike Growth Factor I Levels in Stage I Breast Cancer Patients. Journal of the National Cancer Institute, 82, 1693-1697.
http://dx.doi.org/10.1093/jnci/82.21.1693
[112] Milazzo, G., Giorgino, F., Damante, G., Sung, C., Stampfer, M.R., Vigneri, R., Goldfine, I. and Belfiore, A. (1992) Cancer Research, 52, 3924-3930.
[113] Frittitta, L., Vigneri, R., Stampfer, M.R. and Goldfine, I.D.J. (1995) Insulin Receptor Overexpression in 184B5 Human Mammary Epithelial Cells Induces a Ligand-Dependent Transformed Phenotype. Journal of Cellular Biochemistry, 57, 666-669. http://dx.doi.org/10.1002/jcb.240570411
[114] Kaleko, M., Rutter, W.J. and Miller, A.D. (1990) Molecular and Cellular Biology, 10, 464-473.
[115] Mountjoy, K.G., Finlay, G.J. and Holdaway, I.M. (1987) Cancer Research, 47, 6500-6504.
[116] Benson, E.A. and Holdaway, I.M. (1982) Cancer Research, 42, 1137-1141.
[117] Belfiore, A., Frittitta, L., Costantino, A., Frasca, F., Pandini, G., Sciacca, L., Goldfine, I.D. and Vigneri, R. (1996) Insulin Receptors in Breast Cancer. Annals of the New York Academy of Sciences, 784, 173-188.
http://dx.doi.org/10.1111/j.1749-6632.1996.tb16235.x
[118] Chappell, J., Leitner, W., Solomon, S., Golovchenko, I., Goalstone, M.L. and Draznin, B. (2001) Effect of Insulin on Cell Cycle Progression in MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 41, 38023-38028.
[119] Reyman, P. (1997) Chemotherapy Principles of Administration. In: Groenwald, S.L., Yarbro, C.H., Goodman, M. and Frogge, M.H., Eds., Cancer Nursing Principles and Practice, 4th Edition.
[120] Dorr, R.T. and Vonn Hoff, D.D. (1993) Cancer Chemotherapy Handbook. 2nd Edition. Appleton & Lange, Norwalk.
[121] Schilsky, R.L., Bailey, B.D. and Chabner, B.A. (1981) Characteristics of Membrane Transport of Methotrexate by Cultured Human Breast Cancer Cells. Biochemical Pharmacology, 30, 1537-1542. http://dx.doi.org/10.1016/0006-2952(81)90378-6
[122] Lippman, M., Bolan, G. and Huff, K. (1976) The Effects of Estrogens and Antiestrogens on Hormone-Responsive Human Breast Cancer in Long-Term Tissue Culture. Cancer Research, 36, 4595-4601.
[123] Monaco, M.E. and Lippman, M.E. (1977) Insulin Stimulation of Fatty Acid Synthesis in Human Breast Cancer in Long Term Tissue Culture. Endocrinology, 101, 1238-1246. http://dx.doi.org/10.1210/endo-101-4-1238
[124] Plich, P.F., Thompson, P.A. and Czech, M.P. (1980) Coordinate Modulation of D-Glucose Transport Activity and Bilayer Fluidity in Plasma Membranes Derived from Control and Insulin-Treated Adipocytes. Proceedings of the National Academy of Sciences of the United States of America, 77, 915-918. http://dx.doi.org/10.1073/pnas.77.2.915
[125] Snyder, A.L., Kann, H.E. and Kohn, K.W. (1971) Inhibition of the Processing of Ribosomal Precursor RNA by Intercalating Agents. Journal of Molecular Biology, 58, 555-565. http://dx.doi.org/10.1016/0022-2836(71)90371-8
[126] Tobey, R.A. (1972) A Simple, Rapid Technique for Determination of the Effects of Chemotherapeutic Agents on Mammalian Cell Cycle Traverse. Cancer Research, 32, 309-316.
[127] Paoletti, C., Lesca, C., Cros, S., Mahy, C. and Auclairs, C. (1979) Ellipticine and Derivateves Induce Breakage of L1210 Cells DNA in Vitro. Biochemical Pharmacology, 28, 345-350.
http://dx.doi.org/10.1016/0006-2952(79)90096-0
[128] Bhuyan, B.K., Faser, T.J. and Li, L.H. (1972) Cell Cycle Phase Specificity and Biochemical Effects of Ellipticine on Mammalian Cells. Cancer Research, 32, 2538-2544.
[129] Saucier, J.M., Festy, B. and Lepecq, J.B. (1971) The Change of Torsion of the DNA Helix Caused by Intercalation. II. Measurement of the Relative Change of Torsion Induced by Various Intercalating Drugs. Biochimie, 53, 973-980. http://dx.doi.org/10.1016/S0300-9084(71)80065-2
[130] Festy, B., Poisson, J. and Paolettic, C. (1975) A New DNA Intercalating Drug: Methoxy-9-Ellipticine to DNA. Cancer Research, 35, 71-76.
[131] Oster, J.B. and Creasey, W.A. (1981) Enhancement of Cellular Uptake of Ellipticine by Insulin Preincubation. European Journal of Cancer and Clinical Oncology, 17, 1097-1103.
[132] Ohnuma, T. and Holland, J.F. (1997) Nutritional Consequences of Cancer Chemo Therapy and Immunotherapy. Cancer Research, 37, 2395-2406.
[133] Shamberger, R.C., Brennan, M.F., Goodgame, J.T., Lowry, S.F., Maher, M.M., Wesley, R.A. and Pizzo, P.A. (1984) A Prospective Randomized Study of Adjuvant Parenteral Nutrition in the Treatment of Sarcomas: Results of Survival and Metabolic Studies. Surgery, 96, 1-13.
[134] Peacock, J.L., Gorschboth, C.M. and Northon, J.A. (1987) Impact of Insulin on Doxorubicin Induced Rat Host Toxicity and Tumor Regression. Cancer Research, 47, 4318-4322.
[135] Chabner, B.A. and Meyers, C.E. (1985) Clinical Pharmacology of Cancer Chemo Therapy. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A., Eds., Cancer, Principles and Practice of Oncology, J.B. Lippincott Company, Philadelphia, 312.
[136] Kafka, M.S. (1974) The Effect of Insulin on the Permeability of Phosphatidyl Choline Bimolecular Membranes to Glucose. Journal of Membrane Biology, 18, 81-94. http://dx.doi.org/10.1007/BF01870104
JCT Subscription


● Iranian news agencies reported that Amiri had, in fact, been a double agent spying on the United States.
아미리는, 사실, 미국의 이중간첩이었다고 이란의 뉴스가 보도했다.
● Therefore a German lawyer who is a spy for the Americans could/will also be a double agent for the BND.
그러므로, 미국을 위하여 간첩일을 하는 독일인 변호사는 또 한편으로는 독일연방정보국의 이중간첩일 수도 있다.
● Germany has arrested an employee of the German Federal Intelligence Agency (BND) for alleged spying on behalf of the United States.
독일정부는 독일연방정보국의 한 직원을 미국을 위해 일하는 간첩혐의로 체포했다.


text:
Q2 Goals Recap
On July 7, 2017 July 7, 2017 By firnhydeIn Arwen, Exavior, faith, Jamaica, Lancelot, Liana, Midas, Thunder, Trooper, Vastrap, Zorro
Oh, but first I must tell y'all that the kiddies are incredible!! But you knew that, right? We are taking FOUR ponies and their little riders to Gauteng Finals and I am so proud of them I might just explode. 😀 Best of all, my riders that didn't make it to Finals are just as talented as those that did, so it's only a matter of time before they get there, too.
So Liana, Vastrap, Zorro and Pennie have all made it and they are all going really very well, particularly Zorro (but don't tell the other ponies I said that). Their kiddos have put in a lot of work this season and I'm so happy to see them being so richly rewarded. But of course we can't lose sight of the real Reason why we're here: they planted, I watered – and our Abba Father gave the increase.
Well, now back to goals. Let's have a look.
Get points for Elementary Medium. Still chipping away at this! It'll pick up now, hopefully, that we're going to more dressage and fewer showing shows. Either way, last quarter we had two points, and now we have five. It is possible to get points one class at a time.
Our Elementary work is slowly improving. The horse is starting to touch the limit of her physical ability (not necessarily her natural talent – but her ability combined with dodgy schooling due to being my first project ever when I was, like, 13) and I don't think we'll ever show seriously at EM, but there's no reason why our Elementary can't be solid. To be fair, though, the problem is more mine than hers. I flounder at the level. I don't know what anything is really supposed to look like and I don't have the opportunity for lots of dressage lessons, so the tests are basically our lessons. I even struggle to remember the longer tests. But it's all a learning experience; my next Elementary horse will be better and this one is a whole lot of fun. Our next show is CHG Leg 5 in the end of August. We have eight weeks before then, including one week off and one week of test riding right before the show, leaving the remaining six weeks to work on our six lowest marks (shoulder-in left, walk-canter transition, medium-working canter transition, turn on the haunches, 20m circle with break of contact, rein back). One movement each week. It will take an art to keep this from stealing the joy of the dance, but one breath at a time, God is taking over the artist inside me.
Don't mess up a show riding/show hack class.
Jump a graded 80cm round.
Do some cross-country lessons and/or go drag hunting. I doubt hunting will be on the calendar this year, but we might just make it to xc lessons at President's Park. Which would be absolutely fabulous (and disgusting preparation for our August show, but whatevs).
Arwen is laying the foundation of my own education. If I ever do go up the grades (and that's really up to God; my dance with Thunder on Sunday showed me that it's not the level that matters, but the threefold cord) nobody will remember Arwen – but I will. Because she went first, and she paved the way.
As we start to see 2018 on the horizon, I am also pondering a foray into another discipline with her next year. Part of me just yearns to go event again, but another part can't justify the expense for a discipline the horse won't excel in. Probably showing. Maybe it'll be time to gird up my loins and face my fear of showing judges.
Exavior
we all still miss him
As y'all know by now, I had to make the decision to sell the big guy. He's with a trainer in Brakpan right now (something I've been too raw to write about – the trainer is lovely and I know he's a lot happier with a job to do, and God sent that miracle for us just like He's sent everything else in Exavior's life) and hopefully he'll met his person soon.
Hack alone and in company. Done! With a child on board (in company), too. He loves his hacks.
Be quiet at shows.
Compete up to 70cm showjumping at training shows. Still winning at 60cm (and kinda bored at the level, too) but I don't think I should make him haul my heavy behind around 70cm. He pops around it at home with kids, and he has a new little partner to finish bringing him on, so as soon as little partner is ready, we'll do it.
Compete up to Prelim at training shows.
Compete at the Nooitie shows. We did all the ones that seem to be happening this year, and he came home with some ribbons, too.
Go cross-country schooling. Fingers crossed for this month!
Stand for grooming and farrier.
Lead and tie up.
Box well. Almost almost there – we can box without a bum rope, but with cookies and with some hesitation.
Be good to bath.
Be good to catch.
Show in-hand. Spring Show was cancelled, but we'll probably send in a video for the E-Show in August because then at least nobody can tell me I have a hairy yak in person, right? She behaves nicely in-hand, trots up and stands square, just needs a polish.
In spring, lunge.
In November/December, do the groundwork and have a rider on, just sitting.
Ah, the joys of the long and dull two-year-old year while your precious, promising creature's withers slowly catch up to its behind. She is wonderful though. I can't wait to sit on her.
Hack reliably in company. We haven't hacked much, with most of the focus on jumping, but he's never put a foot out of line in walk and trot – I'm quite happy. I still wouldn't lead a long hack on him… but to be fair, I've got hacking nerves, so I wouldn't lead a long hack on anything very much except Arwen (and Trooper).
School Novice dressage. As evidenced by the appearance of a topline, he's carrying himself a LOT better. Still not brilliant, but to be fair to him, with his body shape and previous schooling brilliance on the flat is going to be a lot to ask. We have most of the Novice 1 to 4 work down. Trot lengthenings and free walk are still a sticky point. His canter work is lovely.
Jump 90cm graded. Heading that way; we're doing 80cm at shows and popping over the odd 90cm height/width fence at home. The horse can do it – he just skips along. It's my nerves that are the problem and that's just going to be a step-by-step process.
So grateful for the spotty one – he has done so much for me already, and continues to do so much with every session.
Reliably do long hacks alone, in company, and wherever without any drama his kid won't laugh off. Very, very close to finishing this one – we haven't been on a super long hack yet, but he's done 45 minutes or so in w/t/c, even with a novice rider. He's lovely.
Do a training show or two at Prelim dressage. Done! With 65% and 67.3% in Prelim 3 and 4, too.
Consistently jump graded at 70cm, preferably clear. He's completing his 70cm rounds, but he still has the odd stop that he likes to throw in, and I just want him to be rid of that habit. I'm not too worried about poles – that's just greenness in his body. I just want him to hunt down the fences.
Lancey is so close to being handed over to Z-kid for good. He just needs to be a little braver at shows.
Do training showjumping shows, up to about 60cm. He is still struggling to figure out that jumping is a thing, but he's very sweet about it.
Do training dressage shows, up to Prelim. Schooling Prelim at home all right.
Be as safe as a house on hacks, mostly in company. You could literally be a one-armed two-year-old with ADHD and hack this thing out without being in any danger.
Be as safe as a house on the ground. Just need to box, then we're good.
Be fully quiet at shows. We haven't been on an outing yet, but I'm aiming for August.
I'm hoping we'll be able to afford to do all the competing we're hoping for – the sale ponies often end up a bit sidelined in favour of the more lucrative training horses. That said, I've given him six weeks off anyway. He's three and a half and has all the basics; I can't expect a whole lot more from him right now.
Thunny spent the first half of the year competing under K at SANESA, but their season is done now, so it's time he and I started to get our duckies in a row.
School all the Novice work, ready to compete next year. Our Prelim is solid; the only movements we have a little trouble with are halting (steady and straight but not square), stretchy trot, and lengthenings, all of which are Novice work anyway. He's played with leg-yields, counter canter and simple changes, but I expect difficulty with lengthenings, so this goal will start with strengthening the basic gaits first.
Jump 70cm courses with confidence. Anybody can see that he's no showjumper, but he'd make a really fun working hunter once he's settled at shows. Since I drag Arwen to HOY anyway, I don't see why he shouldn't come along and plop around the in-hand, show hunter and working hunter.
Do our pre-flatwork short hacks calmly. These are hit-and-miss at the moment. He's either perfect, or he sees a terrifying sparrow and bolts. He has a proper Friesian bolt too – no bucking, but practically impossible to stop except by means of a vicious one-rein, which I don't really want to do to him. I don't want to get killed either though, so he'll have to have a few until he learns that whoa means whoa.
Onwards and upwards. Glory to the King.
2017dressageequestrianeventinggoalsGodGod's planhorsesJeremiah 29:11JesusNooitgedachtershowingshowjumping
This Week in Dressage: Shoulder-in Left

redpajama_set_name: RedPajamaCommonCrawl


"Today we're coming with the Opera 55 stable update. Among the other things, it includes: improvements for the Setting page, fixes for disappearing "X" button, when hovering over the last tab, and highlighted non-active tab, when closing the last one."
5MB down not acceptable! It has been like this for many weeks. It used to be 10MB down.
rudrick last edited by rudrick @rudrick This post is deleted!
- Fix for Linux crash on full screen startup.
- Improvements for sliding toolbar "Install Chrome Extensions" on the Chrome Web Store.
- Improvements of styling on the Settings page.
"This update modifies also the behavior of strings for settings on the Settings pages, which have an off switch. Previously, turning off a particular setting - for example location access - would change the string from 'Ask before accessing (recommended)' to 'Blocked'.
Now, the settings string will not change after you turn off a particular setting. The 'Ask before accessing (recommended)' string will remain, if you were to turn off location setting. We hope this makes it more clear that the setting is off, and not that something is 'Blocked'."
When press "+" at the end of last tab - opens new tab, but pointer not in address field and i can't input text immediately. I must click on address field to enter text. Is it bug or i must reset settings?
Should be fixed on next update.
This build includes fixes for the issues: no focus in the address bar, when opening a new tab, and missing search box on the start page.
I recently posted my dislike for Opera 55.0.2994.56 as it had changed the "settings" page so drastically, I was given a flag setting to change so it would disable this new setup #new-md-settings. Any chance they will be adding a switch to toggle "new or old" preference?
There was also talk about not having the ability to delete individual cookies, I found where to do that but it is very obscure!
I have updated to version 55.0.2994.59 but have used the above mentioned flag to revert back to the "old" settings choices. Also I have turned off "autoupdate".
Most probably the old settings page will be removed when they consider the new one ready.
@gofer83 There is no bug, it's a legal issue.
Can I somewhere find an explanation of this issue? Would like to know what is the cause.
There are several topics about it on Opera for Linux forum.
Basically a license is required to play some codecs and since Opera doesn't have such license, it depends on the OS to play those codecs.
The problem is that Opera can only use the library (or whatever it's called) compatible with the Chromium version its based on, what may cause problems when the library is updated.
Hi @sharkyca, it will be rather like @leocg says, that it's going to be replaced with the new layout for the Settings page.
Hi @gofer83, you can read here the reply by the Opera's employee Arjan van Leeuwen.


text:
Home→Reading Symphony Orchestra
Reading Symphony Orchestra
Saturday February 6th 2016 7:30 pm - 10:00 pm
Great Hall Reading University
Join Reading Symphony Orchestra in the University Great Hall for our fabulous winter concert. We are delighted to be joined by the young and incredibly talented Harvey Liu for Beethoven's Piano Concerto No. 1. Harvey (12) is the winner of the RSO / Hickies Young Musicians' Competition 2015 and has recently made it through to the Keyboard Category Final of the BBC Young Musicians' Competition 2016 – a competition which has launched the careers of internationally-acclaimed artists including Alison Balsom, Nicola Benedetti, Natalie Clein and Stephen Hough. Hear Harvey as he prepares to compete in the Keyboard Category Final in Cardiff on 6 March 2016.The second half of the concert will feature Shostakovich's Symphony No. 5. Written in response to his fall from Stalinist favour in 1936, the symphony heralded Shostakovich's return and was seen as a phenomenal success by both the Soviet authorities and the public. The symphony is both triumphant and melancholy, and received a standing ovation of over half-an-hour at its first performance in 1937. Our concert starts with Glinka's rollicking overture to the opera Ruslan and Ludmilla – one of the best-known orchestral showcases around. A concert not to be missed Tickets: £15 adults; £13 concessions; £5 students and under-18s
RG6 6AH
tickets@rso.org.uk
http://www.rso.org.uk/
@rso_reading


The Dow Jones Industrial Average closed higher despite Federal Reserve concerns over slowing global growth. tumbled 29.2% after the biotech company dropped a late-stage trial for aducanumab, an Alzheimer's disease drug. Stocks ended the day in positive territory Thursday as investors shrugged off the Federal Reserve's warning of slowing economic growth and President Donald Trump's comments on China tariffs.


text:
News (World)
Serbian prime minister & her partner make history by welcoming newborn son
The country is celebrating as the two women welcome their new son, Igor.
Belgrade Pride: Authenticity in the face of violence
"I've never said these things aloud to another person. It feels… good."
Lesbian nominated to be prime minister of Serbia
The historically homophobic Balkan state must still approve her selection, and its decision is expected next week.
Serbian police cordon off central Belgrade to protect pride march
Serbia has since sought to boost gay rights as part of its bid to join the European Union.
Serbia's new center-right government to include lesbian minister
"I am only interested in her results in the hard work that lies ahead," incoming Prime Minister Vucic said, while announcing the composition of his new Cabinet.
Serbia pride march calls for solidarity with migrants
Hundreds attending a tightly-secured gay pride event on Sunday in Serbia called for solidarity with tens of thousands of migrants passing through the Balkan country.
Serbia LGBT pride march takes place undisturbed as riot police stand guard
BELGRADE, Serbia — Waving rainbow-colored flags, several hundred gay activists proceeded undisturbed through downtown Belgrade on Sunday thanks to the protection of thousands of riot police. The march advanced for only several hundred meters through the empty Belgrade streets where shops were closed and public transport was stopped….
Head of Serbia church denounces planned gay pride march
BELGRADE, Serbia — The head of Serbia's influential Christian Orthodox church on Tuesday denounced a gay pride march planned for the weekend, adding to tensions over the event, which has faced threats from extremists. Patriarch Irinej said in a statement that the "shameless" event casts a moral shadow on Serbia — a conservative …
Brutal attack leaves German gay rights activist with life-threatening injuries
BELGRADE, Serbia — A German man who took part in a gay rights conference suffered life-threatening brain injuries when he was severely beaten in downtown Belgrade on Saturday, Serbian police and gay activists said. The identity of the 27-year-old man has not been released. Jovanka Todorovic, from the Labris gay and lesbian group,
Serbia government faces criticism over gay pride ban
BELGRADE, Serbia — European Union officials have criticized the Serbian government's decision to ban a gay pride march for the third consecutive year because of threats from right-wing groups.


With the holidays in tow, the highlight for many during this season is gathering with family and friends and enjoying your favorite holiday treats. Cookies, candied yams, and pies can often be found at every turn when attending holiday festivities. Here are some tips that will help you to enjoy your holiday to the fullest while not increasing your waistline.


android / platform / art / 0d2af30^! / .
Fix multi-image TODOs in patchoat.
- Reinstated checks that were still valid (one check was removed).
- Removed unused path that patches only images.
-    LOG(ERROR) << "Patchoat is not supported with compressed image files "
-  // Nothing special to do right now since the image always needs to get patched.
-  // Perhaps in some far-off future we may have images with relative addresses that are true-PIC.
-  // give it away now and then switch to a more manageable ScopedObjectAccess.
-  // Create the map where we will write the image patches to.
output_oat_fd >= 0,  // was it opened from FD?


SsangYong's Alexandra Whitley has been noted as well on her way to making a mark in the motor racing industry.
Whitley (22) is a born and bred Australian, but moved to New Zealand two years ago and now works for leading motor vehicle company SsangYong.
Not only does the SsangYong dealership team provide the talented youngster with sponsorship for her racing aspirations, but employed her through the company providing her with extra support and great learning opportunities.
Whitley grew up in a racing family in Toowoomba with her father a keen speedway driver. Although she has the tarmac tracks on her mind and aspires to be the first female to compete in the V8 Supercars competition.
She was recently one of few selected to attend the Elite Motorsport Academy in Otago where she learnt about dealing with the media, fitness, nutrition, mental and physical training and establishing sponsorship.
Whitley will be one to watch when she contends the popular 2016/17 SsangYong Racing Series which kicks off at the ITM Auckland SuperSprint (V8 Supercars round) at Pukekohe Park on 4th-6th November 2016.


text:
'Outstanding Senior Citizen' a lifelong volunteer
Zach Tuggle
Bucyrus Telegraph Forum
BUCYRUS – Virginia Hammontree is busier in retirement than most people are on the job, and she seems to be getting a little busier every week.
Her extensive volunteerism has earned her the Crawford County Outstanding Senior Citizen Award, which was presented in August by the Ohio District 5 Area Agency on Aging.
"It's an annual thing they do," Hammontree said. "For each county."
But Hammontree almost wishes they'd picked someone else for the honor.
"I'm not about me," she said.
That mentality is part of what has led to her to help others throughout most of her life.
Hammontree grew up in a small Missouri town called De Soto, which is about half the size of Bucyrus. She and her husband, Pat, didn't stay there long after marriage. His job in the railroad industry took them to four states before they finally settled in Bucyrus in 1993.
"Our girls were seniors in high school when we moved here," Hammontree said.
They both went away to college, but then returned to central Ohio to start families. None of them plan to leave any time soon.
"This has become home, it really has," Hammontree said.
Hammontree worked for 30 years in the banking business, serving as a teller, an accountant and secretary. She made a lot of friends along the way, and has always tried to keep people the focus of her efforts.
Helping is something Hammontree started doing as a child, in school, at church and wherever she was able. It was during a Bible study in the early '80s that she realized God was calling her to be a servant to everyone in her community.
"That's what I'm here for," Hammontree said.
One of her first projects at her new home was helping with Contact Crawford County.
"It's a 24-hour help line," Hammontree said. "You can call us with whatever crisis is happening in your life."
Volunteers take a four-hour shift as frequently as possible to man the phone line. They've convinced people to not commit suicide, and helped children with homework. One night Hammontree spoke to a man who was having trouble with a new pair of shoes, so she directed him to the store to buy inserts. That solved his problem.
"It was the most important thing in his life at the time," Hammontree said.
Providing food for the hungry is another of Hammontree's weekly tasks. She helps both young and old remain nourished, and has found a lot of help accomplishing the task.
"This community is a very generous community," she said. "It is amazing."
She's in charge of a backpack meal program at Bucyrus City Schools. She and other volunteers send enough food home with children on Fridays to last them the entire weekend. The program started five years ago when teachers noticed children were in poor spirits on Mondays because they weren't being fed over the weekend.
Hammontree sends meals home to about 110 students every weekend. If she gets extra food or donations, she sends the students home with extra food to share with their families.
"If the child's hungry, they're probably not the only ones in the house who are hungry," Hammontree said.
She and her husband also take meals to a couple dozen senior citizens each week through the Crawford County Council on Aging's program called Meals on Wheels. They spend about an hour a day, three days a week, taking meals to people who cannot get out and get food on their own. Hammontree said sometimes she is the only visitor they have all week.
The sad reality Hammontree is facing is that she and her husband and their fellow volunteers are now doing more work than ever, as the older volunteers can no longer help, and younger generations are not stepping up to fill in behind them. She plans to keep working hard, because she knows it's what God wants her to do.
"Every organization that works with volunteers is hurting," Hammontree said. "The people who volunteer know what it takes, and are willing to do what they need to do to make it work."
ztuggle@gannett.com
Twitter: @zachtuggle


The generous invitation to create new works for JUXTAPOSE had me thinking about constructing my first surrealist assemblage, but I had no specific concept in mind. I had some ruined wood frames, ornate in style, and started cutting them with a mitre saw to form a Swiss cross. To be honest, I didn't want to use that symbol, so it was easy to "cancel" the idea by rotating it 45 degrees, and now I had an X to "mark the spot." Dead end? There had to be more to it than that. I shifted my attention to completing a collage, and I must have unwittingly assigned the problem to my subconscious, because I awoke after a night's sleep with the total solution in my head. How can one explain something like that (or Dada, for that matter)?
A few words of caution, however: Don't actually plug it in.
The customary Valentine's Day division of labor: I make a card and my sweetheart bakes a cherry pie. Don't you agree that I get the better side of this deal?
Obviously, collage is not made out of nothing, but the ingredient elements can be little more than rubbish — material of scant value, or literally with no intrinsic worth. Find the most rejected, undesirable, recycling-bin content, castoffs destined for a landfill, or something which never should have been thoughtlessly tossed out a truck window in the first place, and you have the potential for art. That idea excites me nearly as much as the ensuing process of reclaiming it for a new purpose.
I won't try to downplay it. I can't recall being as enthusiastic about having my work included in an exhibition. This is shaping up to be a milestone, must-see show.
You are currently browsing the The Collage Miniaturist weblog archives for February, 2016.


Feminine yet versatile cardigan in blue, made from a premium viscose blend that light to wear. The fabric features a lurex yarn for a subtle sparkle, adding a little extra to your look. This essential piece kan we matched with our Cintana top, but basically works with anything.


text:
// Copyright 2018 The Oppia Authors. All Rights Reserved.
//
// Licensed under the Apache License, Version 2.0 (the "License");
// you may not use this file except in compliance with the License.
// You may obtain a copy of the License at
//
//      http://www.apache.org/licenses/LICENSE-2.0
//
// Unless required by applicable law or agreed to in writing, software
// distributed under the License is distributed on an "AS-IS" BASIS,
// WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.
// See the License for the specific language governing permissions and
// limitations under the License.

/**
 * @fileoverview Facilitates communication between the current interaction
 * and the progress nav. The former holds data about the learner's answer,
 * while the latter contains the actual "Submit" button which triggers the
 * answer submission process.
 */

import { downgradeInjectable } from '@angular/upgrade/static';
import { Injectable } from '@angular/core';

import { ContextService } from 'services/context.service';
import { PlayerPositionService } from
  'pages/exploration-player-page/services/player-position.service';
import { PlayerTranscriptService } from
  'pages/exploration-player-page/services/player-transcript.service';
import { InteractionAnswer } from 'interactions/answer-defs';
import { InteractionRuleInputs } from 'interactions/rule-input-defs';
import { Observable, Subject } from 'rxjs';

export interface InteractionRulesService {
  [ruleName: string]: (
    answer: InteractionAnswer, ruleInputs: InteractionRuleInputs) => boolean;
}

type SubmitAnswerFn = () => void;

type OnSubmitFn = (
  answer: string, interactionRulesService: InteractionRulesService) => void;

type ValidityCheckFn = () => boolean;

type PresubmitHookFn = () => void;

@Injectable({
  providedIn: 'root'
})
export class CurrentInteractionService {
  constructor(
    private contextService: ContextService,
    private playerPositionService: PlayerPositionService,
    private playerTranscriptService: PlayerTranscriptService) {}
  private static submitAnswerFn: SubmitAnswerFn = null;
  private static onSubmitFn: OnSubmitFn = null;
  private static validityCheckFn: ValidityCheckFn = null;
  private static presubmitHooks: PresubmitHookFn[] = [];
  private static answerChangedSubject: Subject<void> = new Subject<void>();

  setOnSubmitFn(onSubmit: OnSubmitFn): void {
    /**
     * The ConversationSkinDirective should register its onSubmit
     * callback here.
     *
     * @param {function(answer, interactionRulesService)} onSubmit
     */
    CurrentInteractionService.onSubmitFn = onSubmit;
  }

  registerCurrentInteraction(
      submitAnswerFn: SubmitAnswerFn, validityCheckFn: ValidityCheckFn): void {
    /**
     * Each interaction directive should call registerCurrentInteraction
     * when the interaction directive is first created.
     *
     * @param {function|null} submitAnswerFn - Should grab the learner's
     *   answer and pass it to onSubmit. The interaction can pass in
     *   null if it does not use the progress nav's submit button
     *   (ex: MultipleChoiceInput).
     * @param {function} validityCheckFn - The progress nav will use this
     *   to decide whether or not to disable the submit button. If the
     *   interaction passes in null, the submit button will remain
     *   enabled (for the entire duration of the current interaction).
     */
    CurrentInteractionService.submitAnswerFn = submitAnswerFn || null;
    CurrentInteractionService.validityCheckFn = validityCheckFn || null;
  }

  registerPresubmitHook(hookFn: PresubmitHookFn): void {
    /* Register a hook that will be called right before onSubmit.
     * All hooks for the current interaction will be cleared right
     * before loading the next card.
     */
    CurrentInteractionService.presubmitHooks.push(hookFn);
  }

  clearPresubmitHooks(): void {
    /* Clear out all the hooks for the current interaction. Should
     * be called before loading the next card.
     */
    CurrentInteractionService.presubmitHooks = [];
  }

  onSubmit(
      answer: string, interactionRulesService: InteractionRulesService): void {
    for (
      let i = 0; i < CurrentInteractionService.presubmitHooks.length; i++) {
      CurrentInteractionService.presubmitHooks[i]();
    }
    CurrentInteractionService.onSubmitFn(answer, interactionRulesService);
  }

  submitAnswer(): void {
    /* This starts the answer submit process, it should be called once the
     * learner presses the "Submit" button.
     */
    if (CurrentInteractionService.submitAnswerFn === null) {
      let index = this.playerPositionService.getDisplayedCardIndex();
      let displayedCard = this.playerTranscriptService.getCard(index);
      let additionalInfo = (
        '\nUndefined submit answer debug logs:' +
        '\nInteraction ID: ' + displayedCard.getInteractionId() +
        '\nExploration ID: ' + this.contextService.getExplorationId() +
        '\nState Name: ' + displayedCard.getStateName() +
        '\nContext: ' + this.contextService.getPageContext() +
        '\nErrored at index: ' + index);
      throw new Error(
        'The current interaction did not ' +
        'register a _submitAnswerFn.' + additionalInfo);
    } else {
      CurrentInteractionService.submitAnswerFn();
    }
  }

  isSubmitButtonDisabled(): boolean {
    /* The submit button should be disabled if the current interaction
     * did not register a _submitAnswerFn. This could occur in
     * low-bandwidth scenarios where the interaction has not finished
     * loading.
     */
    if (CurrentInteractionService.submitAnswerFn === null) {
      return true;
    }
    /* Returns whether or not the Submit button should be disabled based on
     * the validity of the current answer. If the interaction does not pass
     * in a _validityCheckFn, then _validityCheckFn will be null and by
     * default we assume the answer is valid, so the submit button should
     * not be disabled.
     */
    if (CurrentInteractionService.validityCheckFn === null) {
      return false;
    }
    return !CurrentInteractionService.validityCheckFn();
  }

  updateViewWithNewAnswer(): void {
    CurrentInteractionService.answerChangedSubject.next();
  }

  get onAnswerChanged$(): Observable<void> {
    return CurrentInteractionService.answerChangedSubject.asObservable();
  }
}
angular.module('oppia').factory('CurrentInteractionService',
  downgradeInjectable(CurrentInteractionService));

redpajama_set_name: RedPajamaGithub


text:
Limiting exposure: DNREC to cap visitors to state parks, wildlife areas
Apr 9th, 2020 · by Mike Finney · Comments: 0
This sign was recently installed by the Delaware Department of Natural Rescources and Environmental Control at Cape Henlopen State Park in Lewes, warning visitors that limitations will be set on the number of guests to safely be allowed at the park. (Submitted photo)
DOVER — With Delawareans already three weeks into Gov. John Carney's stay-at-home order due to the coronavirus pandemic and the weather beginning to warm up, many people are itching to get out of the house and enjoy some fresh air for a change.
The problem is it seems too many people have been doing that all at once inside Delaware State Parks and its wildlife areas, putting social distancing in jeopardy, according to Shawn Garvin, secretary of the Delaware Department of Natural Resources and Environmental Control.
That is why DNREC officials announced on Thursday that they will take steps, when necessary, to limit the numbers of visitors within state parks and wildlife areas following recent crowding and public health concerns, particularly at Delaware's beach state parks. Public beaches statewide are closed under the state of emergency except for exercise, dog-walking and some vehicle surf-fishing under restricted conditions.
Beginning today, administrators of parks and wildlife areas will begin to limit vehicle access at times when visitor usage is observed to be a cause of crowding and preventing safe social distancing. The vehicle limits will be implemented by DNREC's Natural Resources Police.
"As the days have gotten nicer and the stay-at-home period endures, we have been increasingly concerned to see the behavior of some visitors to our state parks and wildlife areas, with full parking lots and increasingly crowded trails," said Secretary Garvin in a phone interview Thursday. "Limiting the number of people when we see too much crowding will allow us to keep these public spaces open for individuals who need a break and fresh air, but to keep everyone safe."
The state parks will be limited on a case-by-case basis, as some are more popular – and bigger, with easier access – than others.
"We are having some crowding issues more at some parks than we are at others," said Secretary Garvin. "We will be working with the superintendents of the parks on the issue of crowding. We're seeing different things statewide as we continue to have the parks remain open.
"We have been running into people not necessarily following the criteria set by the governor during his state of emergency declaration and now we need to take steps to protect folks from each other. As the weather gets nicer and nicer, we're seeing an uptick in crowding at our parks."
Nikki Lavoie, spokesperson for DNREC, said that during this national health crisis the public should limit their visits to the parks for when they need a break or fresh air and to avoid peak times, which is often mid-afternoon. She added that people should stay for shorter times so others have an opportunity to use the public spaces and trails.
"We understand this period is a difficult time," Ms. Lavoie said. "For this reason, Delawareans may continue to experience our parks and wildlife areas, to embrace nature and stay active, but they must maintain social distance from each other and follow other requirements.
"We will be constantly assessing the visitation and conditions in the parks and wildlife areas. We will act accordingly in the interest of public health."
DNREC provided the following tips and guidance for those visiting parks and wildlife areas during the COVID-19 outbreak:
• While parks and wildlife areas are large, many visitors use the same amenities. Visitors should try to spread out from others within these areas.
• Bathrooms remain closed in all parks and wildlife areas and at boat ramps.
• Out-of-state visitors must observe a 14-day quarantine before entering a park or wildlife area.
• Responsible social distancing practices should always be maintained, even while outside.
• All currently allowable activities are subject to change.
These provisions all come under the authority of Gov. John Carney's state of emergency declarations and have the force and effect of law. Any failure to comply with the provisions contained in a declaration of a state of emergency or any modification to a state of emergency can constitute a criminal offense.
Currently, the parks plan to limit the number of visitors by observation, however, Secretary Garvin didn't discount eventually putting a limit on visitors to parks if guests aren't following social-distancing guidelines.
"It depends on if we have a park that is showing that we're just getting sheer large (numbers) of visitors at one time," said Secretary Garvin. "Eventually, we may count numbers and cap it off, but right now we are utilizing many visuals and are taking each park on a case-by-case basis. Some parks have very distinct entrances and large parking lots, while others are smaller."
DNREC said that if anyone is concerned about an individual or group in any state park or wildlife area they may contact DNREC's Natural Resources Police via Tip411, DNREC's smartphone app, or by calling the 24-hour DNREC Dispatch Center at 302-739-4580. Tip411 allows the public to easily report concerns. The app is available for free download by searching DENRP via the Google Play Store or the iTunes App Store.
For the latest information on COVID-19 in Delaware, visit de.gov/coronavirus.
Helpful Coronavirus links
Delaware Division of Health Coronavirus Page
CDC: About the Coronavirus Disease 2019
CDC: What to do if You Are Sick
Johns Hopkins Coronavirus Resource Center
AP News Coronavirus Coverage
Reopening Delaware: Resources for Businesses
Delaware Phase 2 guidance
Have a question, tip, or resources about the coronavirus pandemic? Submit it to our newsroom and we'll do what we can to provide answers.
Tags:DNREC · Featured · Parks


As part of the continuing efforts to rein in inappropriate dermatological care, the FSDDS in April 2010 led a coalition of health care providers opposing efforts to allow electrologists to perform laser hair removal without the benefit of an on-site physician. Backed by representatives from the Florida Academy of Phyiscian Assistants, the Florida Society of Plastic Surgeons, and the Florida Medical Association, FSDDS President Albert J. Nemeth, M.D. and General Counsel Chris Nuland convinced the Florida Board of Medicine to allow the current rule, which requires direct physician supervision of electrologists performing laser hair removal. to remain intact.
While this victory was important, it is but part of an ongoing struggle by the FSDDS to control what sees as the unlicensed practice of medicine in many medical spas. Whether it be laser hair removal by electrologists, dermal filler injection by nurses, or other medical procedures being performed by non-physicians, the FSDDS has consistently advocated that these paraprofessionals must operate under the direct supervision of a physician. Not only does direct supervision simply make sense from a patient safety perspective, but Florida explicitly states that medical assistants and electrologists performing laser hair removal work under the "direct supervision and responsibility" of the supervising physician. Moreover, nurses receive statutory protections from accusations of the improper practice of medicine only if they work under the direct supervision of a physician.
Although ARNPs and physician assistants are exempt from the direct supervision requirement, physicians are reminded why these professionals are called "physician extenders." They are meant to be part of a physician-led team, and the physician therefore bears the ultimate responsibility for their actions. FSDDS members should always ensure that those who work under their licenses work only within the scope of their training and professional licensure.


The second Annual Meeting of the Regional Cooperation Council (RCC) was held in Istanbul on 22 June 2010. It was jointly organised by the South-East European Cooperation Process (SEECP) Chairmanship-in-Office of the Republic of Turkey and the RCC Secretariat, back-to-back with the SEECP Summit.
The RCC Secretary General presented the organization's Strategy and Work Programme 2011-2013 and his Annual Report on regional cooperation in South East Europe for endorsement by the Annual Meeting. The participants also exchanged views on developments in regional cooperation in South East Europe of relevance for the RCC framework, as well as challenges ahead.
The Annual Meeting endorsed the nomination proposal for appointment of the RCC Secretary General for the period starting on 1 January 2011, given that the three-year mandate of Secretary General Hido Biscevic was to expire on 31 December 2010.
The RCC Annual Meeting meets at the level of Senior Civil Servants or above. It is open to other countries, international organizations and partners as guests upon request to and/or the initiative of the Secretary General following the consent of the members of the RCC Board.
Agenda of the meeting is available HERE.
Programme od the event is available HERE.
List of participants is available HERE.
The 2009-2010 Annual Report of the RCC Secretary General on regional cooperation in South East Europe is available HERE.
The RCC Strategy and Work Programme for 2011-2013 is available HERE.
Press Release on this event is available HERE.
Introductory remarks by RCC Secretary General Hido Biscevic at this meeting are available HERE.
Speech by the Minister of Foreign Affairs of the Republic of Turkey, Ahmet Davutoğlu, at the second RCC Annual Meeting is available HERE.
Speaking points of the EU Commissioner for Enlargement and European Neighbourhood Policy, Stefan Fuele, at the RCC Annual Meeting in Istanbul are available HERE.


text:
Rail Freight Campaign
Hertfordshire MPs Oliver Dowden (Hertsmere), Anne Main (St Albans) and Bim Afolami (Hitchin & Harpenden), have written a joint letter calling for the site of the proposed Radlett rail freight terminal to be used for housing instead.
In a letter to the Leader of Hertfordshire County Council, Cllr David Williams, the MPs set out their support for a Park Street garden village while urging Cllr Williams not to sell the site to rail freight developers, Helioslough.
Anne Main said, 'We have to make the case for housing over the completely unwanted rail freight interchange.
'There is a proven housing need in St Albans with many young people and families crowded out of the market.'
The decision to examine the site and the garden village proposal was taken by a meeting of the St Albans Planning Policy Committee on 18 June 2018.
The site is currently largely owned by Hertfordshire County Council. Like any public body, the County Council are under a fiduciary duty to make sure they get best value for money for taxpayers. This includes considering offers to buy surplus land owned by the County Council.
In the case of the rail freight site, if the County Council received an offer for the land from the rail freight developers, this duty means they may well have no choice but to sell.
However, if the site was designated in the St Albans Local Plan as suitable for housing development, the value of the land would increase enormously.
Mrs Main said, 'We must deliver the homes my constituents need and this site provides a good opportunity to do just that.
'I hope the council are able to push ahead with housing on this site instead a rail freight terminal that would have little benefit to St Albans residents and could have a major detrimental impact on rail users.'
The letter to Cllr Williams came following a meeting in Parliament between Mr Dowden, Mrs Main and the campaigning group STRIFE, who have been working to stop the terminal since it was first proposed 2009.
Hertsmere MP Oliver Dowden said, 'I have always said I do not want any development of this green belt land. But if it must be developed, it is ludicrous that the land can have planning permission for a disruptive and unnecessary rail freight terminal, but bids for desperately needed homes cannot be considered.
'As a result I am very pleased that St Albans Council are now considering the site and the proposal for a garden village for inclusion within their Local Plan.
'It is important to make clear to the County Council that there is still another option on the table and they should not sell the land to the rail freight developers.
'I do not believe Hertfordshire County Council are required to sell the site to Helioslough.
'However, should they be ultimately required to sell, I believe that the proper discharge of their fiduciary duty means they need to consider the potential increased value of the land should it be included in the St Albans Local Plan for housing.
'Any premature sale of the site therefore risks significantly undervaluing it and would not achieve best value for the taxpayers of Hertfordshire.'
Mr Dowden, Mrs Main and Mr Afolami's letter to Herts County Council


Abstract: A permissive chromatin environment coupled to hypertranscription drives the rapid proliferation of embryonic stem cells (ESCs) and peri-implantation embryos. We carried out a genome-wide screen to systematically dissect the regulation of the euchromatic state of ESCs. The results revealed that cellular growth pathways, most prominently translation, perpetuate the euchromatic state and hypertranscription of ESCs. Acute inhibition of translation rapidly depletes euchromatic marks in mouse ESCs and blastocysts, concurrent with delocalization of RNA polymerase II and reduction in nascent transcription. Translation inhibition promotes rewiring of chromatin accessibility, which decreases at a subset of active developmental enhancers and increases at histone genes and transposable elements. Proteome-scale analyses revealed that several euchromatin regulators are unstable proteins and continuously depend on a high translational output. We propose that this mechanistic interdependence of euchromatin, transcription, and translation sets the pace of proliferation at peri-implantation and may be employed by other stem/progenitor cells.


For the past decade IPT has been a leader in developing unique and varied solutions to a range of panel needs. Our expertise rests in our ability to marry certain components and create application-specific panels. Those solutions may be in the form of wood panels, polypropylene bonded to plywood, wood laminates, painted wood panels, coated panels, aluminum bonded to wood or any one of a hundred other combinations that may be necessary in meeting your specific requirements. IPT has readily available products that are fully-developed and easily ordered or we can work with you to develop a specific solution that precisely meets your needs. We can't wait to prove our desire to serve you and expertise as leaders in innovating panels for every conceivable application.


Healthcare professionals and the general public view healthcare analytics with optimistic skepticism. As the following examples illustrate, it's time for healthcare analytics vendors to show results.
In early 2016, a study conducted by the New England Journal of Medicine stated that healthcare executives and administrators see population health as the future of healthcare, but doctors and clinicians remain unconvinced.
These statements validate NPR's conclusion that healthcare analytics is nearing the end of a hype cycle. A hype cycle is when a technology debuts to great fanfare then, either because expectations were too high or companies failing to follow through on promises, the public becomes disenfranchised. However, as that disenfranchisement fades and expectations level off, the technology is able to show its true potential and become a productive tool.
If healthcare analytics is moving out of a hype cycle, then it's time for vendors to showcase the true value of the technology.
A new case study published by GlobalHealth serves as a good example. The study closely examines how GlobalHealth, a regional payer located in Oklahoma, used predictive analytics to create a proactive outreach program that transformed the company, saved millions in healthcare costs, and improved the health of its members.
One of GlobalHealth's priorities in creating their outreach program was finding an analytics partner with a solution that could seamlessly integrate and evolve with the company. They selected our company, VitreosHealth, based in Dallas, Texas.
"We looked at some national vendors and didn't get much from them," said Scott Vaughn, CEO of GlobalHealth. "The vendor we finally selected had a lot of substance: very strong data architecture and legitimate interfacing capabilities.
GlobalHealth instituted their proactive outreach program on Jan. 1, 2014. Since then, the company has made a dramatic improvement in the health of its members.
The case study examines several reasons for the success of GlobalHealth's outreach program and concludes that one of the main reasons was finding the right vendor who could seamlessly integrate with the company and deliver on their promises.


text:
GALLERY IN SUMMER RECESS UNTIL 2 FEBRUARY 2022
JOHN BOKOR EXHIBITION REVIEWED BY ERIN MCFADYEN IN 'ARTIST PROFILE' ONLINE
By Nicholas Thompson | September 29, 2021 | Comments Off on JOHN BOKOR EXHIBITION REVIEWED BY ERIN MCFADYEN IN 'ARTIST PROFILE' ONLINE
John Bokor's recent still life paintings – shown alongside earlier interiors at Nicholas Thompson Gallery – sound out the shape of absence, even in their colourific and textural richness.
In recent months, video footage of empty CBDs – especially Melbourne and Sydney – has been circulating through my varied social media feeds. Populating this footage are shopping strips empty of foot traffic, six-lane motorways with a solitary Uber delivery person being blown through on a bike, and huge multi-million dollar stadiums full of silence. These images – and they're almost stills, really – have an eerie half-liveliness about them. The scenes might feel post-apocalyptic, or they might feel like something from deep historical time; the worst bit of this is, of course, that these are scenes neither of the future nor the past, but from now. While emptiness has sat outside waiting for us, many will have just passed a winter of intense interiority.
In John Bokor's A single bloom, 2021, two chairs face into a table. There is, per the work's title, a single pink flower in a vase, two plates, a few cups, and what looks to be a drawing, perhaps of an animal form. Dark shadows spool out from each pictured object: perhaps this is a nod to Margaret Preston and the Australian still life tradition into which Bokor enters in his work, or perhaps it is just late in the day. Certainly the light is warm enough to suggest this latter option. In fact, the whole image is "warm" – the titular "bloom" is robust and pink like a cheek, the edges of the crockery bright and slightly glowing, everything (including the table) round and soft at the edges. And yet, I'm drawn continually into the unoccupied space the shadows fall across. The plates are empty. The chairs are empty.
Bokor is "not interested in the hard concrete facts of the objects," in his still lifes, and says his "aim is to paint a response to the subject rather than a documentation of it." Many of these works were made on the Umbi Gumbi Artist Residency at Cuttagee Beach this year, though some older paintings of interiors are shown as well. Though his approach to genre, and his use of space in the picture, have developed over time, what echoes across the different periods of his work is the sense that a human occupant – sometimes even named, as in Sallie's table, 2014, and Hendrik and Julianna's sitting room, 2014 – has just stepped out of the scene. Rather than simple documents of what remains in empty rooms, though, these paintings do indeed feel like responses to the phenomenon of unoccupied space: to me, twelve weeks into Sydney's lockdown, the "warmth" of Bokor's interior object studies feels like a reaching towards the vanished people who would have sat, drawn, drank, and remarked on the roses in these scenes. Even the tabletops do this reaching – see how the perspective of Bokor's paintings tilts their surfaces down toward the viewer like extended palms.
In light of this, it seems entirely fitting that these paintings should be viewable, for the foreseeable future, primarily through Nicholas Thompson Gallery's website. Our looking must echo Bokor's painting. That is, we can look at the richness in front of us, and use this to better understand the shape of the cavities which have grown around us over the past, say, eighteen months (though perhaps it is much longer).
Erin McFadyen for Artist Profile (online) 29 September 2021
Posted in John Bokor
FOLLOW GALLERY ON INSTAGRAM
© 2021 Nicholas Thompson Gallery. All Rights Reserved.
Nicholas Thompson Gallery acknowledges and pays respect to the Wurundjeri People of the Kulin Nation, the Traditional Owners of the land on which the gallery operates.


text:
Tiger's Defense Comes Through as LSU Defeats Florida, 17-6
Jay Walker
Jay Walker Published: October 12, 2013
Stacy Revere/Getty Images Sport
The LSU Tigers haven't been known for their defense.
Until Saturday.
The Tigers' ran their record to 6-1 as they defeated the Florida Gators, 17-6 at Tiger Stadium Saturday at Tiger Stadium in Baton Rouge.
The LSU defense, which was considered to be the weak link on the team, did a yeoman's job against the Florida offense, holding the Gators to just two field goals in leading the Tigers to their sixth win of the season.
The Tigers became bowl eligible for the 14th straight season in holding the Gators' offense to just 240 yards of offense. IOt was the first time in 32 years that the Tigers held Florida without a touchdown.
Lamin Barrow had 13 tackles to pace the Tigers, while Craig Loston added nine more, as LSU overcame four double digit drives to defeat the Gators.
Zach Mettenberger completed only 9-17 passes for 152 yards, but the Tigers' running game picked up the slack as LSU got a game high 121 yards on 19 carries to pace the Tigers' offense.
The crowd at Tiger Stadium was announced at 92,980.
Filed Under: florida gators, jeremy hill, lsu tigers, sec. southeastern conference, zach mettenberger
Categories: Local Sports, National Sports


PORTLAND, Ore. – December 8, 2008 – In the battle over the care and use of the world's oceans, one voice is often lost in the debate: that of the fisherman.
A technology now exists to address that issue, and it's just received a national award for innovation.
The Mellon Award follows a worldwide, public nomination process, and ten recipients were selected by a committee that included Vint Cerf, Vice President and Chief Internet Evangelist of Google, and the so-called "Father of the Internet"; Sir Timothy Berners-Lee, Director of the World Wide Web Consortium; Mitchell Baker, CEO, Mozilla Corp.; John Seely Brown, former Chief Scientist, Xerox Corp.; and John Gage, partner, Kleiner, Perkins, Caufield, and Byers.
"Open OceanMap combines the best of GIS-based approaches for facilitating the capture, organization and dissemination of scientific data on marine life with a totally open set of tools," said Ira Fuchs, VP for Research in Information Technology at the Mellon Foundation. "This is just the beginning. The same tool set could be used for orchestrating the collection of other kinds of environment data anywhere — this is the type of innovation that has the potential to make a real difference for fishermen, public policy planners, and others. Open OceanMap could provide a powerful platform for enhancing pro-amateur science; for example, by offering a way to get high school students more engaged in environmental studies."
Ecotrust advocates for better approaches to living, ones that incorporate social, economic and environmental well-being. Over nearly 20 years, Ecotrust has converted $60 million in grants into more than $300 million in capital for local people, businesses, and organizations from Alaska to California. Ecotrust is a new kind of organization, one that integrates public and private purpose and for-profit and non-profit structures. Ecotrust's many innovations include co-founding the world's first environmental bank, starting the world's first ecosystem investment fund, creating a range of programs in fisheries, forestry, food, farms and children's health, and developing new scientific and information tools to improve social, economic and environmental decision-making. Ecotrust works locally in ways that promise hope abroad, and it honors and incorporates the wisdom of native and first nation knowledge in its work. More on the Web at www.ecotrust.org.


text:
Q: How is the get URL generated in HTML forms? I've been reading about the get method to submit form data.
So, the data from the form is appended to the action attribute's value of the form with ? as a separator.
What I fail to understand is, how I can correctly predict what the URL from a form submission will be.
I mean, lets say a form looks like this:
<form method="get" action="foobar.com/search">
  User Name : <input type="text" name="uname"></input>

  Name : <input type="text" name="name"></input>

  <input type="submit" value="Submit"></input>
</form>

When the submit button is clicked, what is the generated URL?
It would be : foobar.com/search?[data encoded here]
But what protocol defines how it is encoded? The name might come before or after the user name.
Is it possible to write a script that would create a template URL for any form so that on replacing the corresponding %s with string data, it would create the correct URL?
THank you.

A: Given an application/x-www-form-urlencoded encoding (the default) and the use of GET, the process is, in brief:
For each control, in the order they appear in the form, if it is a successful control:

*

*If not the first item, add a &

*URL encode the name of the field

*Add an =

*URL encode the value of the field

The complete process for constructing a form data submission is described in the HTML 5 specification (specifically in The application/x-www-form-urlencoded encoding algorithm).

Is it possible to write a script that would create a template URL for any form so that on replacing the corresponding %s with string data, it would create the correct URL?

Since it isn't always possible to predict which controls will be successful until the form is submitted, no.

A: The order of parameters makes absolutely no difference, since it is an associative array.
That said, I'm fairly sure all browsers will send the variables in the order they appear in the source. So in your case it will be ?uname=[input]&name=[input]

redpajama_set_name: RedPajamaStackExchange